AMG509-CD3-hIgG1

Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. Xaluritamig contains two identical humanized anti-STEAP1 fragment antigen–binding domains that bind STEAP1-expressing cells, an anti-CD3 single-chain variable fragment domain that binds T cells to facilitate T cell–mediated lysis, and an effectorless Fc domain that extends serum half-life. The avidity from two STEAP1-binding domains drives high potency against STEAP1-expressing tumor cells.